Umeclidinium bromide
- Generic Name
- Umeclidinium bromide
- Brand Names
- Anoro, Anoro Ellipta, Incruse Ellipta, Trelegy Ellipta, Rolufta Ellipta (previously Rolufta), Incruse Ellipta (previously Incruse)
- Drug Type
- Small Molecule
- Chemical Formula
- C29H34NO2
- CAS Number
- 869185-19-3
- Unique Ingredient Identifier
- GE2T1418SV
- Background
Umeclidinium is a long-acting muscarinic antagonist (LAMA) used as a maintenance treatment for symptoms of chronic obstructive pulmonary disease (COPD). COPD is a progressive obstructive lung disease characterized by shortness of breath, cough, sputum production, and chronically poor airflow with a forced expiratory volume in 1 second (FEV1) of less than 80%...
- Indication
Umeclidinium is approved by the FDA and Health Canada for the maintenance treatment of patients with chronic obstructive pulmonary disease (COPD). Additionally, umeclidinium also exists as combination products with vilanterol or vilanterol and fluticasone furoate. Both products were indicated for the maintenance treatment of COPD, but only the umeclidinium/v...
- Associated Conditions
- Asthma, Chronic Obstructive Pulmonary Disease (COPD)
- Associated Therapies
- -
Sanofi/Regeneron Pharmaceuticals' DUPIXENT Approval Marks a Significant Shift
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.